A Study of TY-9591 With Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor NSCLC

NCT06672068 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

NSCLC

Interventions

DRUG: TY-9591 80mg QD+pemetrexed+Cisplatin/Carboplatin
DRUG: TY-9591 160mg QD+pemetrexed+Cisplatin/Carboplatin

Sponsor

TYK Medicines, Inc